Founded on the principle of precision immunology, Samdolite Pharmaceuticals is advancing a new class of anti-inflammatory therapies by targeting the cellular initiators of inflammation—mast cells—rather than downstream cytokines alone. While most anti-inflammatory drugs focus on blocking individual cytokines, Samdolite’s approach is built on the understanding that cytokines are signals, not the source, of inflammatory disease. Mast cells act as upstream sentinels of the innate immune system, orchestrating inflammatory cascades through rapid degranulation and recruitment of secondary immune cells such as neutrophils. By selectively and reversibly inhibiting mast cell activation, Samdolite aims to interrupt inflammation at its point of origin—before cytokine release and amplification, tissue damage, and chronic disease establishment occur. This cell-targeted strategy is designed to provide broader and more durable disease control across multiple inflammatory conditions, while avoiding the safety and systemic risks associated with immune cell depletion or chronic cytokine suppression. By addressing the biological drivers rather than their downstream messengers, Samdolite seeks to redefine how inflammatory diseases are treated—starting at the source.
